These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35441791)

  • 1. Lidocaine for dinutuximab-associated pain? A multicenter retrospective observational cohort study.
    Featherly J; Baxter Wojnowicz S; Steidl K; Burgess J
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29653. PubMed ID: 35441791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
    Mastrangelo S; Rivetti S; Triarico S; Romano A; Attinà G; Maurizi P; Ruggiero A
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
    Lode HN; Ehlert K; Huber S; Troschke-Meurer S; Siebert N; Zumpe M; Loibner H; Ladenstein R
    Br J Cancer; 2023 Nov; 129(11):1780-1786. PubMed ID: 37813959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
    Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
    Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
    Greenwood K; Foster JH
    Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective investigation of the relationship between neuroblastoma response to anti-GD2 monoclonal antibodies and exposure to opioids for pain management.
    Morgan KJ; Dudas A; Furman WL; McCarville MB; Shulkin BL; Lu Z; Darji H; Anghelescu DL
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30069. PubMed ID: 36308746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma.
    Garrovillo K; Garrett J; Bollin K; Nasraty F; Sikand H
    J Oncol Pharm Pract; 2020 Dec; 26(8):2058-2065. PubMed ID: 32356686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Greenwood KL; Foster JH
    Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
    Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
    J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
    Lode HN; Ladenstein R; Troschke-Meurer S; Struppe L; Siebert N; Zumpe M; Ehlert K; Huber S; Glogova E; Hundsdoerfer P; Eggert A; Zaniewska-Tekieli A; Balwierz W; Wieczorek A
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava.
    Achbergerová M; Hederová S; Hrašková A; Kolenová A
    Medicine (Baltimore); 2022 Jan; 101(4):e28716. PubMed ID: 35089239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
    Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinutuximab: A Review in High-Risk Neuroblastoma.
    Hoy SM
    Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yoga as a non-pharmacologic therapy to reduce dinutuximab-induced pain in patients with neuroblastoma.
    Parisio KN; Kulp T; Heil M; Li Y; Dalton K; McGrath M; Carlowicz C; Donnelly M; Bagatell R; Jubelirer T
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30845. PubMed ID: 38192171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhombencephalitis and longitudinal extensive myelitis associated with dinutuximab use in high-risk neuroblastoma.
    Atak F; Aydın GB; Öncel İ; Öz S; Oğuz KK
    Turk J Pediatr; 2023; 65(3):523-530. PubMed ID: 37395971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.